If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
In England, anatomy was the subject of the first public lectures given in any science; these were provided by the Company of Barbers and Surgeons in the 16th century, joined in 1583 by the Lumleian lectures in surgery at the Royal College of Physicians.
==== During pregnancy ==== MDMA is a moderately teratogenic drug (i.e., it is toxic to the fetus). In utero exposure to MDMA is associated with a neuro- and cardiotoxicity and impaired motor functioning. Motor delays may be temporary during infancy or long-term. The severity of these developmental delays increases with heavier MDMA use. MDMA has been shown to promote the survival of fetal dopaminergic neurons in culture.
Witnesses included FDA officials. They looked into several areas: the delay in reporting by Menu Foods, the lack of federal inspections of pet food facilities, and incomplete reporting by the FDA since the start of the recall. During the hearing Senators Durbin and Byrd criticized the government's response during the recall. Durbin specifically criticized the lack of any regular inspection practices or quality control with regards to pet food safety. Senator Kohl criticized the FDA's communication to the public about recalled foods, noting that volunteer websites had more detailed and easier-to-access information about the extent of the problem and which specific foods are of concern than FDA's online resources which Kohl said was contradictory of itself at times, and which the FDA official giving testimony admitted to being difficult to navigate. On 18 April 2007, Senator Durbin and Representative DeLauro met with US FDA Commissioner von Eschenbach to discuss the additional rice protein recalls and learned that the Chinese government was blocking outside attempts to investigate the contamination. In response, they sent a letter to Zhou Wenzong, China's Ambassador to the United States saying in part that "contaminated batches of wheat gluten and rice protein responsible for these events were imported from China" and that "no level of melamine should be found in pet or human food" and asking for visas for inspectors from the United States.
Beginning with X-Men #107 (October 1977), Wolverine began wearing a new brown-and-tan costume. X-Men #116 (December 1978) first introduces Wolverine's healing factor, and issue #124 (August 1979) first suggests that he has a reinforced skeleton. The same year, Wolverine appeared in his first solo story, "At the Sign of the Lion", published in the UK in Marvel Comic #335 (March 1979).
=== Distribution === Ibutilide has a relatively large volume of distribution among individual subjects, which is about 11L/kg. Approximately 40% of the drug is bound with plasma albumin of healthy volunteers in a trial. This is also approximately close to patients with atrial fibrillation and flutter.
Sources: en.wikipedia.org
The authentic idea of the unity of the Slavic people was all but gone after World War I, described with the maxim "Versailles and Trianon have put an end to all Slavisms". During the Cold War, all Slavic peoples were in union under the dominance of the USSR, but pan-Slavism was rejected as reactionary to Communist ideals, and this unity was largely put to rest with the fall of communism in Central and Eastern Europe in the late 1980s, leading to the breakup of federal states such as Czechoslovakia and Yugoslavia. Varying relations between the Slavic countries exist nowadays; they range from mutual respect on equal footing and sympathy towards one another through traditional dislike and enmity, to indifference. No forms, other than culture and heritage oriented organizations, are currently considered forms of rapprochement among the countries with Slavic origins. The political parties which include Pan-Slavism as part of their program usually live on the fringe of the political spectrum, or are part of controlled and systemic opposition in Belarus, Russia and occupied territories, as part of an irredentist pan-slavist campaign by Russia. A political concept of Euro-Slavism evolved from the idea that European integration will solve issues of Slavic peoples and promote peace, unity and cooperation on equal terms within the European Union. The concept seeks to resist strong multicultural tendencies from Western Europe, the dominant position of Germany, opposes Slavophilia, and typically encourages democracy and democratic values.
The National Center for Complementary and Integrative Health (NCCIH) is a United States government agency which explores complementary and alternative medicine (CAM). It was created in 1991 as the Office of Alternative Medicine (OAM), and renamed the National Center for Complementary and Alternative Medicine (NCCAM) before receiving its current name in 2014. NCCIH is one of the 27 institutes and centers that make up the National Institutes of Health (NIH) within the United States Department of Health and Human Services. NCCIH has been criticized for funding and marketing pseudoscientific medicine and quackery.
t is age of the sample, D* is number of atoms of the radiogenic daughter isotope in the sample, D0 is number of atoms of the daughter isotope in the original or initial composition, N(t) is number of atoms of the parent isotope in the sample at time t (the present), given by N(t) = N0e−λt, and λ is the decay constant of the parent isotope, equal to the inverse of the radioactive half-life of the parent isotope times the natural logarithm of 2. The equation is most conveniently expressed in terms of the measured quantity N(t) rather than the constant initial value No. To calculate the age, it is assumed that the system is closed (neither parent nor daughter isotopes have been lost from system), D0 either must be negligible or can be accurately estimated, λ is known to high precision, and one has accurate and precise measurements of D* and N(t). The above equation makes use of information on the composition of parent and daughter isotopes at the time the material being tested cooled below its closure temperature. This is well established for most isotopic systems. However, construction of an isochron does not require information on the original compositions, using merely the present ratios of the parent and daughter isotopes to a standard isotope. An isochron plot is used to solve the age equation graphically and calculate the age of the sample and the original composition.
== External links == Granulocyte+Colony-Stimulating+Factor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P09919 (Granulocyte colony-stimulating factor) at the PDBe-KB.
Sources: en.wikipedia.org
=== Leptomeninges === The arachnoid and pia mater are sometimes together called the leptomeninges, literally "thin meninges" (Greek: λεπτός "leptos"—"thin"). Acute meningococcal meningitis can lead to an exudate within the leptomeninges along the surface of the brain. Because the arachnoid is connected to the pia by cobweb-like strands, it is structurally continuous with the pia, hence the name pia-arachnoid or leptomeninges. They are responsible for the production of beta-trace protein (prostaglandin D2 synthase), a major cerebrospinal fluid protein.
Countercurrent exchange and cocurrent exchange are two mechanisms used to transfer some property of a fluid from one flowing current of fluid to another across a barrier allowing one way flow of the property between them. The property transferred could be heat, concentration of a chemical substance, or other properties of the flow. When heat is transferred, a thermally-conductive membrane is used between the two tubes, and when the concentration of a chemical substance is transferred a semipermeable membrane is used.
=== Foreign political and diplomatic figures === Henry Cruger* (1758), member of the Parliament of Great Britain 1774–1790 and the New York State Senate Isaac Wilkins (1760), judge, member of the Nova Scotia House of Assembly Thomas Henry Barclay (1772), United Empire Loyalist; member of the 6th General Assembly of Nova Scotia Tang Shaoyi* (1882), first premier of the Republic of China William Sanford Evans (1895), Manitoba politician, mayor of Winnipeg 1909–1911 Pixley ka Isaka Seme (1906), founder and president of the African National Congress Wellington Koo (1909), president of the Republic of China and China's ambassador to the United States; Chinese delegate to the Paris Peace Conference, 1919 and the League of Nations; judge on the International Court of Justice 1957–1967 Jun Ke Choy (1915), former mayor of Hangzhou, chairman of China Merchants Group, and founder of the Chinese Culture Center Yu Tsune-chi (1922), Chinese ambassador to Italy and Spain, delegate to the San Francisco Conference, United Nations and the International Labour Organization Mario Laserna Pinzón (1948), Colombian diplomat and educator; founded the Universidad de Los Andes Colin Hughes (1949), first commissioner of the Australian Electoral Commission Uldis-Ivars Grava (1958), Latvian parliamentarian, former director of Latvijas Televīzija and chairman of American Latvian Association Johan Jorgen Holst (1960), Norwegian minister of Defence and Foreign Affairs; heavily involved with the Oslo Accords Yossi Alpher (1964), former Mossad officer and director of the Jaffee Center for Strategic Studies at Tel Aviv University Dore Gold (1975), Israeli political advisor and diplomat; former ambassador to the United States Toomas Hendrik Ilves (1975), president of Estonia Carson Wen (1975), three-time Hong Kong deputy to the National People's Congress and former vice chairman of the Democratic Alliance for the Betterment and Progress of Hong Kong Geoffrey Onyeama (1977), Nigerian minister of Foreign Affairs since 2015, son of Nigerian justice Charles Onyeama Michael Oren (1977), Israeli historian and former Israeli ambassador to the United States Miloon Kothari (1979), United Nations special rapporteur on adequate housing Kim Hyun-jong (1981), former South Korean minister of Trade and Special Advisor to President Moon Jae-in Ken Ofori-Atta (1984), Ghanaian economist and investment banker and current minister for Finance and Economic Planning, member of the Ofori-Atta family Akiva Tor (1985), Israeli ambassador to South Korea Abdullah bin Khalid bin Sultan Al Saud (2010), Saudi Arabia's permanent representative to the United Nations in Vienna, ambassador to Austria, Slovakia and Slovenia, great-grandson of Ibn Saud
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.